Skip to main content
main-content

Exenatide

News

09-15-2017 | Exenatide | EASD 2017 | News

EXSCEL: Near miss for exenatide cardioprotection

The results of the Exenatide Study of Cardiovascular Event Lowering study show that the glucagon-like peptide-1 receptor agonist has a neutral cardiovascular effect, the investigators have reported at the EASD annual meeting, in Lisbon, Portugal.

09-13-2017 | Glucagon-like peptide-1 agonists | EASD 2017 | News

Incretins research update

One of the first original research sessions of EASD 2017 included updates from the TECOS, SUSTAIN 6, and DURATION-7 and -8 trials.

09-13-2017 | Exenatide | EASD 2017 | News

DURATION-8: Exenatide efficacy durable to 1 year

The 52-week findings of the DURATION-8 trial show durable glycemic control with the combination of exenatide and dapagliflozin in patients with type 2 diabetes.

Read more

Related topics

Superior

Related

Journal articles and book chapters

07-03-2017 | Exenatide | Review | Article

A review of the long-term efficacy, tolerability, and safety of exenatide once weekly for type 2 diabetes

Genovese et al. review the data concerning the treatment of type 2 diabetes with once weekly exenatide with special reference to its long-term efficacy, tolerability, and safety.

Genovese S, Mannucci E, Ceriello A. Adv Ther 2017;34:1791–1814. doi:10.1007/s12325-017-0499-6

03-16-2017 | Glycemic control | Review | Article

Metrics for glycemic control: From HbA1c to continuous glucose monitoring

In this review, Kovatchev discusses topics related to the assessment, quantification, and optimal control of glucose fluctuations in diabetes mellitus which are crucial for providing accurate information to the patient and physician.

Nat Rev Endocrinol 2017;13:425–436. doi:10.1038/nrendo.2017.3

Author:
Boris P. Kovatchev

11-10-2016 | Type 2 diabetes | Review | Article

Clinical Pharmacokinetics and Pharmacodynamics of Antihyperglycemic Medications in Children and Adolescents with Type 2 Diabetes Mellitus

The authors discuss the prevalence of obesity and type 2 diabetes in children and adolescents and summarize published studies on the safety and effectiveness of antihyperglycemic medications in this population.

Akhlaghi F et al. Clin Pharmacokinet 2017; 56: 561–571. doi:10.1007/s40262-016-0472-6